Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00183443 · ClinicalTrials.gov registry record · Phase 3
Treatment of Mania Symptoms With Drug Therapy
A Phase 3 study of Schizophrenia and Bipolar Disorder, sponsored by Palo Alto Veterans Institute for Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT00183443: Completed Phase 3 study of Schizophrenia and Bipolar Disorder, sponsored by Palo Alto Veterans Institute for Research.
NCT00183443 is a Phase 3 study of Schizophrenia and Bipolar Disorder that has completed, run by Palo Alto Veterans Institute for Research. The registered enrollment target is 75 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00183443, a Phase 3 study of Schizophrenia and Bipolar Disorder, has completed, sponsored by Palo Alto Veterans Institute for Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will determine the effectiveness of three different drug therapies in treating the symptoms of mania.
Primary Outcome
Symptoms of mania, as measured by Young Mania Rating Scale. The scale is eleven-item multiple choice diagnostic questionnaire (range 0-60), which psychiatrists use to measure the severity of manic episodes in children and young adults. Typically, 20 is the minimum score required for mania. Higher scores represent increased severity of mania symptoms.
Conditions Studied
Interventions
- DRUG Lithium
- DRUG Quetiapine
- DRUG Divalproex-extended release (DVP-ER)
Study Locations (1)
California
- VA Palo Alto Health Care System - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2005-02 |
| Est. Completion | 2010-11 |
| Phase | Phase 3 |
What the finished NCT00183443 record still lists
NCT00183443 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (66% lower).
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 3 interventions - of which Lithium is the first listed.
NCT00183443 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00183443 about?
NCT00183443 is a clinical study titled "Treatment of Mania Symptoms With Drug Therapy". This study will determine the effectiveness of three different drug therapies in treating the symptoms of mania.
What is the current status of trial NCT00183443?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 75 participants. The study started on 2005-02. Estimated completion is 2010-11.
What conditions does trial NCT00183443 study?
This clinical trial studies the following conditions: Schizophrenia, Bipolar Disorder.
What interventions are being tested in trial NCT00183443?
The interventions under investigation include: Lithium (DRUG), Quetiapine (DRUG), Divalproex-extended release (DVP-ER) (DRUG).
Who is sponsoring clinical trial NCT00183443?
This trial is sponsored by Palo Alto Veterans Institute for Research, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00183443 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00183443's enrollment target sits among peer trials
75 171st of 315 higher than 144 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
RECRUITING · Phase 3
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
RECRUITING · Phase 3
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RECRUITING · Phase 3
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia